Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients ( = 25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1-21) and ibrutinib 560 mg (days 1-28) of 28-day cycles. The MTD for lenalidomide was 20 mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92 months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67 > 30%). R2I was safe and tolerable in patients with R/R MCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2023.2259528 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.
ACG Case Rep J
January 2025
Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada.
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel immunotherapy for the treatment of refractory malignancies. While various complications have been described previously, sclerosing cholangitis has not been reported. We report the first description of sclerosing cholangitis secondary to Tecartus CAR-T therapy in a 67-year-old man with refractory stage IV mantle cell lymphoma.
View Article and Find Full Text PDFNonlinearity of the post-spinel transition and its expression in slabs and plumes worldwide.
Nat Commun
January 2025
Center for Advanced Radiation Sources, University of Chicago, Chicago, IL, USA.
Phase transitions in the mantle control its internal dynamics and structure. The post-spinel transition marks the upper-lower mantle boundary, where ringwoodite dissociates into bridgmanite plus ferropericlase, and its Clapeyron slope regulates mantle flow across it. This interaction has previously been assumed to have no lateral spatial variations, based on the assumption of a linear post-spinel boundary in pressure and temperature.
View Article and Find Full Text PDFEx Vivo Propagation of Pinctada Birnavirus Using Mantle Tissue Fragment Culture: Application for Measuring Replication at Different Temperatures, TCID Assay, and UV Sensitivity.
Pathogens
January 2025
Japan Fisheries Research and Education Agency, Pathology Division, Aquaculture Research Department, Fisheries Technology Institute, Minami-Ise 516-0193, Mie, Japan.
Pinctada birnavirus (PiBV) is the causative agent of summer atrophy in pearl oyster ( (Gould)). The disease, which induces mass mortality in juveniles less than 1 year old and abnormalities in adults, was first reported in Japan in 2019. Research on the disease has been hindered by the lack of cell lines capable of propagating PiBV.
View Article and Find Full Text PDFAdult-Onset Pediatric-Type Follicular Lymphoma of the Parotid Gland.
Cureus
December 2024
Biomedical Sciences, University of Chicago, Chicago, USA.
Pediatric-type follicular lymphoma (PTFL) is an extremely rare B-cell lymphoma that primarily affects children and young adults, typically in individuals under 25 years old, with a median age of 15 years. Here, we report a rare case of PTFL in a 27-year-old adult male who presented with a slow-growing mass near his left ear. Initial CT scans of the neck revealed two oval-shaped, smooth, well-defined, homogeneously enhancing soft tissue density lesions in the superficial lobe of the left parotid gland.
View Article and Find Full Text PDFPhase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
Leuk Lymphoma
January 2025
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!